首页> 外文期刊>Biochemical and Biophysical Research Communications >Pre-immunization of donor lymphocytes with GITR agonistic antibody enhances antitumor immunity in autologous hematopoietic stem cell transplantation
【24h】

Pre-immunization of donor lymphocytes with GITR agonistic antibody enhances antitumor immunity in autologous hematopoietic stem cell transplantation

机译:具有聚环毒剂抗体的供体淋巴细胞预防增强了在自体造血干细胞移植中的抗肿瘤免疫力

获取原文
获取原文并翻译 | 示例
           

摘要

The lymphopenic condition following autologous hematopoietic stem cell transplantation (HSCT) enhances the proliferation of T cells by engaging tumor-associated antigens, leading to the alteration of the T-cell repertoire towards antitumor immunity. However, cure by autologous HSCT alone have rarely occurred in the clinical setting. Since tumor-reactive lymphocytes preferentially proliferate during reconstitution of the immune system, we examined whether the priming of donor lymphocytes can strengthen the antitumor effect by HSCT in a CT26 murine colon cancer model. The systemic administration of an anti-glucocorticoid-induced TNF receptor (GITR) agonistic antibody (Ab) significantly increased the number of CT26-responsive T cells but not that of auto-reactive lymphocytes in donor mice. The infusion of non-primed and GITR Ab-primed donor lymphocytes suppressed the CT26 tumor growth, and only the primed lymphocytes eliminated tumors in all the treated mice. The frequency of CT26-responsive T cells was elevated in recipient mice infused with both primed and non-primed lymphocytes until 4 weeks after transplantation, while the frequency in recipients with primed lymphocytes was markedly elevated compared with that in mice harboring non-primed lymphocytes at 2 weeks. The frequencies of regulatory T cells and myeloid-derived suppressor cells were elevated in recipient mice infused with primed and non-primed lymphocytes 2 weeks after transplantation, and returned to normal levels by week 4. The combination of autologous HSCT with pre-immunization of donor lymphocytes is a promising strategy to induce strong antitumor immunity. (C) 2018 The Authors. Published by Elsevier Inc.
机译:自体造血干细胞移植(HSCT)之后的淋巴通态条件通过接合肿瘤相关的抗原来增强T细胞的增殖,导致T细胞曲目朝向抗肿瘤免疫的改变。然而,仅在临床环境中仅通过自体HSCT治愈。由于肿瘤反应性淋巴细胞在免疫系统的重构期间优先增殖,因此我们检查了供体淋巴细胞的启动是否可以通过HSCT在CT26鼠结肠癌模型中加强抗肿瘤作用。抗糖皮质激素诱导的TNF受体(GITR)激动抗体(AB)的全身施用显着增加了CT26响应性T细胞的数量,但不是供体小鼠中的自动活性淋巴细胞的数量。输注非引发和GITR AB引发的供体淋巴细胞抑制了CT26肿瘤生长,并且仅在所有处理的小鼠中只消除了底部淋巴细胞。 CT26-响应性T细胞的频率在接受者小鼠中升高,在移植后4周内,在妊娠和非灌注淋巴细胞中升高,而具有灌注淋巴细胞的接受者的频率明显升高,与患有非灌注淋巴细胞的小鼠相比显着升高2周。调节性T细胞和霉菌衍生的抑制细胞的频率在移植后2周内与底部注入的受体小鼠升高,并恢复到正常水平,并恢复到正常水平4.自体HSCT与施用预防仪的组合淋巴细胞是一种诱导强烈抗肿瘤免疫力的有希望的策略。 (c)2018作者。 elsevier公司发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号